@article{oai:obihiro.repo.nii.ac.jp:00004778,
 author = {Banzragchgarav, Orkhon and Ariefta, Nanang R. and Murata, Toshihiro and Myagmarsuren, Punsantsogvoo and Battsetseg, Badgar and Battur, Banzragch and Batkhuu, Javzan and Nishikawa, Yoshifumi and 西川, 義文},
 journal = {Parasitology International},
 month = {Dec},
 note = {application/pdf, 179 compounds in a Mongolian compound library were investigated for their inhibitory effect on the in vitro growth of Plasmodium falciparum and Toxoplasma gondii. Among these compounds, brachangobinan A at a half-maximal inhibition concentration (IC50) of 2.62 μM and a selectivity index (SI) of 27.91; 2-(2′-hydroxy-5′-O-methylphenyl)-5-(2″,5″-dihydroxyphenyl)oxazole (IC50 3.58 μM and SI 24.66); chrysosplenetin (IC50 3.78 μM and SI 15.26); 4,11-di-O-galloylbergenin (IC50 3.87 μM and SI 13.38); and 2-(2′,5′-dihydroxyphenyl)-5-(2″-hydroxyphenyl)oxazole (IC50 6.94 μM and SI 11.48) were identified as potential inhibitors of P. falciparum multiplication. Additionally, tricin (IC50 12.94 μM and SI > 23.40) was identified as a potential inhibitor of T. gondii multiplication. Our findings represent a good starting point for developing novel antimalarial and anti-Toxoplasma therapeutics from Mongolian compounds.},
 title = {Evaluation of Mongolian compound library for potential antimalarial and anti-Toxoplasma agents},
 volume = {85},
 year = {2021}
}